Clinical impact of sentinel lymph node biopsy in patients with thick (>4 mm) melanomas |
| |
Authors: | Ian White Jeanine Fortino Brendan Curti John Vetto |
| |
Affiliation: | 1. Division of Surgical Oncology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA;2. Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA |
| |
Abstract: | BackgroundThe role of sentinel lymph node status (SLNS) in thick melanoma is evolving. The purpose of this study was to determine the prognostic value of SLNS in thick melanoma.MethodsA retrospective analysis of 120 prospectively collected clinically node-negative thick melanomas over 5 years was performed. Patient (age/sex) and tumor (thickness, ulceration, SLNS, mitoses, metastases, and recurrence) features were collected. Multivariate analysis was performed using Cox proportional hazard model.ResultsFactors predictive of positive SLN included male sex, ulceration, and high mitoses. Factors associated with positive SLN had higher local–regional recurrence and metastases than negative SLN. SLNS and tumor thickness impacted 5-year disease–free survival (DFS) and overall survival (OS). Positive SLN, ulceration, age, and mitoses were independent predictors of DFS/OS.ConclusionsNonulcerated/lower mitoses thick melanomas had lower positive SLN rates. Positive SLN develop recurrence and metastases and have worse OS/DFS. SLNS is an important prognosticator for OS/DFS. Sentinel lymph node biopsy delineates prognostic groups in thick melanomas and can impact management. |
| |
Keywords: | Thick Melanoma Sentinel lymph node biopsy |
本文献已被 ScienceDirect 等数据库收录! |
|